Keytruda and Abnormal behavior - a phase IV clinical study of FDA data

Summary:

Abnormal behavior is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Lenvima, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Abnormal behavior when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Abnormal behavior?

Abnormal behavior is found to be associated with 1,381 drugs and 1,941 conditions by eHealthMe. Check the latest studies of Abnormal behavior.

On Apr, 24, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 23 people (0.04%) have Abnormal behavior.

Among these 23 people:

How long have people been on Keytruda when they have Abnormal behavior? *

What is the gender of people who have Abnormal behavior when taking Keytruda? *

female: 47.83 %
male: 52.17 %

What is the age of people who have Abnormal behavior when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Abnormal behavior? *

Altered State Of Consciousness (altered state of mind): 5 people, 21.74%
Confusional State: 5 people, 21.74%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 3 people, 13.04%
Aggression: 3 people, 13.04%
Weakness: 3 people, 13.04%
Pain: 3 people, 13.04%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 13.04%
Delirium (wild excitement): 3 people, 13.04%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 13.04%
Renal Disorder (kidney disease): 3 people, 13.04%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 4 people, 17.39%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 13.04%
Endometrial Cancer: 3 people, 13.04%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 8.70%
Endometrial Cancer Recurrent: 2 people, 8.70%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 8.70%
Delirium (wild excitement): 2 people, 8.70%
High Blood Pressure: 2 people, 8.70%
Neuralgia (pain in one or more nerves): 2 people, 8.70%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Abnormal behavior?

- Check whether Abnormal behavior is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Abnormal behavior:

Abnormal behavior (1,381 drugs)

Browse all the conditions that are associated with Abnormal behavior:

Abnormal behavior (1,941 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.